Development History
2003
Founding of QR Science and Technology Development Co., Ltd, headquarter in Wuhan
2004
Establish QR-SIPI Joint Research Center with Shanghai Institute of Pharmaceutical Industry
2005
Founding of QR Pharmaceuticals Co., Ltd, production site for Finished Dosage Forms (FDFs)
2006
L-O L-A lyophilized powder for injection approved and GMP certified by CFDA
Product launch for L-O L-A in China
2007
Establish QR-Tongji Joint Laboratory with Tongji College of Pharmacy
2009
GMP certified by CFDA for L-O L-A granules
Founding of ZY Pharmaceuticals Co., Ltd, production site for APIs and intermediates
2011
Start Wuhan Biolake R&D Center, Wuhan National Bio-industry Base
2012
FasudileMesylate for injection approved by CFDA
2013
Product launch for "Fasudile Mesylate for injection (Lang Lai?)" in the Chinese market
2014
Product launch for "Sofalcone Dry Suspension (Rui Lang?)" in the Chinese market
2017
Established the company “Drug Safety Committee” for Adverse Drug Reaction Monitoring
2018
IND approval for new drug project QR01019(New Drug Categary 2.1)
2019
Strategic transform towards a big data based management system